Key Insights

Highlights

Success Rate

92% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

5.9%

1 terminated out of 17 trials

Success Rate

91.7%

+5.2% vs benchmark

Late-Stage Pipeline

12%

2 trials in Phase 3/4

Results Transparency

27%

3 of 11 completed with results

Key Signals

3 with results92% success

Data Visualizations

Phase Distribution

10Total
Not Applicable (2)
P 1 (4)
P 2 (2)
P 3 (2)

Trial Status

Completed11
Recruiting3
Terminated1
Unknown1
Not Yet Recruiting1

Trial Success Rate

91.7%

Benchmark: 86.5%

Based on 11 completed trials

Clinical Trials (17)

Showing 17 of 17 trials
NCT06007690Phase 3RecruitingPrimary

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

NCT07421739RecruitingPrimary

Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects

NCT07338968Not Yet RecruitingPrimary

A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma

NCT04417530Phase 2Completed

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

NCT03052127Phase 1Completed

Study in Subjects With Small Primary Choroidal Melanoma

NCT02875652Not ApplicableCompletedPrimary

Circulating Tumoral DNA in Choroidal Melanoma (ctDNA MU)

NCT03941379RecruitingPrimary

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

NCT05266430TerminatedPrimary

Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

NCT01460810Not ApplicableCompletedPrimary

Safety and Efficacy of Silicone Oil Tamponade for Surgical Attenuation of Radiation Damage in Choroidal Melanoma

NCT00344799CompletedPrimary

Cytogenetic Study of Ocular Melanoma

NCT00680225Phase 3CompletedPrimary

Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma

NCT00765921Phase 1CompletedPrimary

Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma

NCT01251978Phase 2CompletedPrimary

Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)

NCT00351728Completed

Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone

NCT01253759CompletedPrimary

Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal Melanoma

NCT00750399Phase 1Completed

Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma

NCT00111046Phase 1UnknownPrimary

Pain Relief - Tramadol Versus Ibuprofen

Showing all 17 trials

Research Network

Activity Timeline